文献速递胸部肿瘤

安罗替尼三线及以上治疗晚期非小细胞肺癌总生存的III期随机临床试验(ALTER 0303)

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2018-01-01

ALTER 0303是一项多中心、双盲、III期随机对照试验,纳入440例中国晚期NSCLC患者,按2:1随机接受安罗替尼12 mg/d或安慰剂。常见≥3级不良事件为高血压和低钠血症。

要点

  • 安罗替尼三线及以上治疗晚期NSCLC显著延长总生存期(HR 0.68)。
  • 安罗替尼显著延长无进展生存期(HR 0.25),并提高客观缓解率和疾病控制率。
  • 主要≥3级不良事件为高血压和低钠血症,总体可耐受。

核心结论

  • 在中国晚期NSCLC患者中,安罗替尼三线及以上治疗可显著延长总生存期和无进展生存期,且耐受性良好,是潜在的三线或以上治疗选择。

研究设计与样本

  • ALTER 0303为多中心、双盲、III期随机临床试验,在中国31家三甲医院入组,2015年3月1日至2016年8月31日筛选606例,最终439例随机(安罗替尼组296例,安慰剂组143例),按2:1分配接受安罗替尼12 mg/d或匹配安慰剂。

主要发现

  • 安罗替尼组客观缓解率和疾病控制率较安慰剂组显著改善。
  • 安罗替尼组最常见的≥3级不良事件为高血压和低钠血症。

关键数值与推荐

  • 入组标准:18-75岁、组织学或细胞学确诊的NSCLC,二线或以上治疗后进展;排除中央型鳞癌伴空洞特征或未控制/控制不足2个月的脑转移患者。

临床怎么用

  • 对于二线或以上治疗后进展的中国晚期NSCLC患者,可考虑安罗替尼12 mg/d作为三线或以上治疗选择。
  • 治疗期间需监测并管理高血压和低钠血症等不良反应。

局限性

  • 本研究仅纳入中国患者,结果外推至其他人群需谨慎。
  • 原文未报告总生存期亚组分析及生活质量详细结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free survival with a potential benefit of overall survival, leading to the phase 3 trial to confirm the drug's efficacy in advanced non-small cell lung cancer (NSCLC). OBJECTIVE: To investigate the efficacy of anlotinib on overall survival of patients with advanced NSCLC progressing after second-line or further treatment. DESIGN, SETTING, AND PARTICIPANTS: The ALTER 0303 trial was a multicenter, double-blind, phase 3 randomized clinical trial designed to evaluate the efficacy and safety of anlotinib in patients with advanced NSCLC. Patients from 31 grade-A tertiary hospitals in China were enrolled between March 1, 2015, and August 31, 2016. Those aged 18 to 75 years who had histologically or cytologically confirmed NSCLC were eligible (n = 606), and those who had centrally located squamous cell carcinoma with cavitary features or brain metastases that were uncontrolled or controlled for less than 2 months were excluded. Patients (n = 440) were randomly assigned in a 2-to-1 ratio to receive either 12 mg/d of anlotinib or a matched placebo. All cases were treated with study drugs at least once in accordance with the intention-to-treat principle. MAIN OUTCOMES AND MEASURES: The primary end point was overall survival. The secondary end points were progression-free survival, objective response rate, disease control rate, quality of life, and safety. RESULTS: In total, 439 patients were randomized, 296 to the anlotinib group (106 [36.1%] were female and 188 [64.0%] were male, with a mean [SD] age of 57.9 [9.1] years) and 143 to the placebo group (46 [32.2%] were female and 97 [67.8%] were male, with a mean [SD] age of 56.8 [9.1] years). Overall survival was significantly longer in the anlotinib group (median, 9.6 months; 95% CI, 8.2-10.6) than the placebo group (median, 6.3 months; 95% CI, 5.0-8.1), with a hazard ratio (HR) of 0.68 (95% CI, 0.54-0.87; P = .002). A substantial increase in progression-free survival was noted in the anlotinib group compared with the placebo group (median, 5.4 months [95% CI, 4.4-5.6] vs 1.4 months [95% CI, 1.1-1.5]; HR, 0.25 [95% CI, 0.19-0.31]; P < .001). Considerable improvement in objective response rate and disease control rate was observed in the anlotinib group over the placebo group. The most common grade 3 or higher adverse events in the anlotinib arm were hypertension and hyponatremia. CONCLUSIONS AND RELEVANCE: Among the Chinese patients in this trial, anlotinib appears to lead to prolonged overall survival and progression-free survival. This finding suggests that anlotinib is well tolerated and is a potential third-line or further therapy for patients with advanced NSCLC. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02388919.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Han B, Li K, Wang Q, et al. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2018. PMID: 30098152. doi:10.1001/jamaoncol.2018.3039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。